The Ministry of Health, Labor and Welfare (MHLW) issued a pharmaceutical safety information bulletin on March 30, calling on physicians to stick to the approved dosage and administration for GlaxoSmithKline K.K.’s (GSK) antiepileptic agent Lamictal (lamotrigine). GSK issued a flash…
To read the full story
Related Article
- GSK Ordered to Issue Blue Letter on Lamictal
February 5, 2015
REGULATORY
- Japan Targets Global-Level Growth for Domestic Patented Drug Market
June 25, 2026
- Paxlovid, Awiqli Braced for NHI Price Cuts after CEAs
June 25, 2026
- Drug Pricing to Be Applied to Oncolys Oncolytic Virus Therapy
June 25, 2026
- Japan Diet Begins Deliberations on Immunization Act Revision
June 25, 2026
- Expert Calls for AMR Ecosystem to Boost Japan Antibiotic Innovation
June 25, 2026
Recent trends are creating a fascinating push-and-pull effect in the talent market. We’re seeing more positions opening up, but also a greater number of candidates available, particularly in the fields of rare diseases and oncology. This “more positions, more candidates”…





